Biotech Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition December 12, 2022
Biotech Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS December 12, 2022
Biotech Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting December 12, 2022
Biotech Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR) Encourages Long-Term EIGR Investors to Contact the Firm December 12, 2022
Biotech (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation December 12, 2022
Biotech Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASH December 12, 2022
Biotech Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea December 12, 2022
Biotech 100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML) December 12, 2022
Biotech Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference December 12, 2022
Biotech Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation December 12, 2022
Search
